Stock News & Analysis

Micron's near-term outlook remains strong, but Nvidia's push to use cheaper memory, rising competition, and Micron's aggressive capacity expansion could create longer-term risks for the stock.

One is profitable with $510 million in revenue; the other burns cash but guards a battery moonshot.

NuScale Power is a money-losing start-up, but it is ready to hit the ground running when it finally gets a customer to sign on the dotted line.

Cerebras has grown revenue 2.5x over eight quarters, while BigBear.ai has stalled — a widening gap that signals very different competitive positions.

The AI boom is alive and well.

Three layers of the AI build-out, one basket -- and the most money goes to the steadiest layer, not the fastest-growing one.

A steady, long-term approach can improve portfolio returns over time.

To hit a price of $400,000 by the end of 2030, Bitcoin will need to deliver a compound annual growth rate of 51%.

Management continues to execute, making the stock look incredibly cheap after its sell-off.

Tripling works out to about 55% a year -- and the company's own target asks for even more.

This under-the-radar industrial technology stock boasts a Superscore of 73 from our Hidden Gems Primary database, part of The Motley Fool's Moneyball Database system. Here's why.

Because of an international push, these two companies are poised for five years of growth.

Consensus price targets over the past three months are very bullish on one of these names and see minimal appreciation for the other.

Nine times since 1990, the conglomerate has finished a year this far behind the market. Seven times, it beat the index the year after.

Oracle shares have crashed on concerns over its AI infrastructure spending.

This under-the-radar software stock boasts a Superscore of 76 from our Hidden Gems Primary database, part of The Motley Fool's Moneyball Database system. Here's why.

Jensen Huang says cybersecurity is likely going to become the next big use case for artificial intelligence (AI).

XLV's 0.08% expense ratio and 22.7% 1-year return outpace IXJ's global reach, but international diversification comes at a cost.

Demand for Novo Nordisk's new GLP-1 pill is rising quickly, while Eli Lilly's new pill faces an important headwind.

This high-performing investment vehicle turned relatively small capital inflows into a huge sum.